Ultragenyx Pharmaceutical Exec Says U.S. Per Patient Wholesale Acquisition Cost For Fayuvi Is Set At $3.95M

Ultragenyx Pharmaceutical has announced that the U.S. wholesale acquisition cost for its drug Fayuvi is set at $3.95 million per patient. This pricing decision is part of the company's strategy to position Fayuvi in the market. The stock ticker for Ultragenyx is RARE.